Finance

Beta
Lists
DFTX:NASDAQ
Definium Therapeutics Inc
$43.60
+20.51%
(+7.42) 1D
Jun 24, 12:40:28 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for DFTX...
Open
$39.25
High
$44.54
Low
$39.25
Mkt. cap
4.76B
Avg. vol.
2.70M
Volume
9.18M
52-wk high
$44.54
52-wk low
$14.62
EPS
-$2.49
Beta
2.37
Shares outstanding
109.07M
No. of employees
106
Open
$39.25
High
$44.54
Low
$39.25
Mkt. cap
4.76B
Avg. vol.
2.70M
Volume
9.18M
52-wk high
$44.54
52-wk low
$14.62
EPS
-$2.49
Beta
2.37
Shares outstanding
109.07M
No. of employees
106
News stories
From sources across the web
Profile
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs. Wikipedia
About Definium Therapeutics Inc
CEORobert Barrow
Employees106
Founded2010
Headquarters-
SectorPharmaceutical industry
Websitedefiniumtx.com
Analyst Ratings
Based on 12 analysts giving stock ratings to DFTX in the past 3 months
Strong Buy
Buy
12
Hold
0
Sell
0
12 month forecast
Based on 12 Wall Street analysts offering 12 month price targets for DFTX in the last 3 months.
Highest
Current $43.60
$74.00 (+69.72%)
Average
$54.82 (+25.73%)
Lowest
$35.00 (-19.72%)
Analyst
Recommendation
Action
Price Target
Projected
Date
Michael Okunewitch
Maxim Group
Buy
Reiterated
$50.00
+14.7%
06/23/2026
Justin Walsh
JonesTrading
Buy
Reiterated
$74.00
+69.7%
06/23/2026
Christopher Chen
Robert W. Baird
Buy
Maintained
$57.00
+30.7%
06/23/2026
Sumant Kulkarni
Canaccord Genuity
Buy
Maintained
$60.00
+37.6%
06/22/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
$70.00
+60.6%
06/23/2026
Francois Brisebois
LifeSci Capital
Buy
Reiterated
$63.00
+44.5%
06/22/2026
Jay Olson
Oppenheimer
Buy
Maintained
$60.00
+37.6%
06/22/2026
Andrew Tsai
Jefferies
Buy
Reiterated
$35.00
-19.7%
06/22/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
-
-
06/22/2026
Brian Abrahams
RBC Capital
Buy
Maintained
$36.00
-17.4%
06/22/2026
Ami Fadia
Needham
Buy
Reiterated
$50.00
+14.7%
06/23/2026
David Amsellem
Piper Sandler
Buy
Reiterated
$48.00
+10.1%
05/08/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$26.00
-40.4%
03/02/2026
Rudy Li
Wolfe Research
Buy
Initiated
$25.00
-42.7%
02/23/2026
Last report
Nov 6, 2025
Fiscal period
Q3 2025
EPS / Est. (USD)
-$0.78 / -$0.50
-54.84%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q3 2025 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
29.81M
30.98M
33.52M
41.48M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
11.09M
14.69M
14.06M
17.74M
Operating expense
40.90M
45.67M
47.58M
59.22M
Total operating expenses
40.90M
45.67M
47.58M
59.22M
Operating income
-40.90M
-45.67M
-47.58M
-59.22M
Other non operating income
-2.23M
-22.54M
-5.06M
-20.05M
EBT including unusual items
-42.74M
-67.26M
-50.44M
-77.10M
EBT excluding unusual items
-42.74M
-67.26M
-50.44M
-77.10M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-42.74M
-67.26M
-50.44M
-77.10M
Net profit margin
-
-
-
-
Earnings per share
-0.50
-0.78
-
-
Interest and investment income
2.77M
2.26M
3.49M
3.46M
Interest expense
-2.34M
-1.27M
-1.27M
-1.24M
Net interest expenses
436.00K
988.00K
2.22M
2.21M
Depreciation and amortization charges
-
-
-
-
EBITDA
-40.90M
-45.66M
-47.57M
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer